Hydroxyurea and Transfusion

Summary

Hydroxyurea and Transfusion is a clinical trial^[1].

Key Facts

• Hydroxyurea and Transfusion is in the country of United States^[2].
• Hydroxyurea and Transfusion's instance of is recorded as clinical trial^[3].
• Hydroxyurea and Transfusion's start time is recorded as +2018-10-30T00:00:00Z^[4].
• Hydroxyurea and Transfusion's end time is recorded as +2020-08-31T00:00:00Z^[5].
• Hydroxyurea and Transfusion's number of participants is recorded as {'unit': '1', 'amount': '+20'}^[6].
• Hydroxyurea and Transfusion's title is recorded as Hydroxyurea and Transfusion: Pilot Study of Combination Therapy for Patients With Sickle Cell Anemia^[7].
• Hydroxyurea and Transfusion's short name is recorded as HAT^[8].
• Hydroxyurea and Transfusion's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+2'}^[9].
• Hydroxyurea and Transfusion's ClinicalTrials.gov ID is recorded as NCT03644953^[10].
• Hydroxyurea and Transfusion's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+24'}^[11].
• Hydroxyurea and Transfusion's research intervention is recorded as hydroxycarbamide^[12].
• Hydroxyurea and Transfusion's clinical trial phase is recorded as phase II clinical trial^[13].
• Hydroxyurea and Transfusion's research site is recorded as Children's National Hospital^[14].
• Hydroxyurea and Transfusion's research subject recruitment status is recorded as active, not recruiting^[15].
• Hydroxyurea and Transfusion's study type is recorded as interventional study^[16].